Non-Alcoholic Fatty Liver Disease

Geoff Farrell, Professor of Hepatic Medicine, Director of Gastroenterology, The Canberra Hospital, AustraliaGeoffrey Farrell graduated MB BS from the University of Tasmania in 1970, and trained in gastroenterology and hepatology at the Royal Prince Alfred and Royal Brisbane Hospitals, the latter with Lawrie Powell with whom he completed an MD on hepatic drug metabolism. He was awarded an NHMRC CJ Martin Fellowship to conduct post-doctoral research in UCSF, and in 1980 returned to Sydney to establish a Liver Research Group at Westmead Hospital. He was promoted to a personal chair in 1993, then accepted the Storr Chair in Hepatic Medicine. He remained Director of the Storr Liver Unit until Jan 2006, when he accepted the position as Professor of Hepatic Medicine with ANU Medical School and Director of Gastroenterology and Hepatology at The Canberra Hospital. He has held many leadership roles in medical research, gastroenterology, editorial boards, and academic medicine, including Editor-in-Chief of Journal of Gastroenterology and Hepatology since November 2006.Geoff Farrell's research interests are in non-alcoholic steatohepatitis, viral hepatitis, drug-induced liver injury, and liver regeneration. He has published 3 books, including the first on non-alcoholic fatty liver disease, and written more than 180 scientific papers and 100 reviews/chapters and editorials in the fields of hepatology and biochemical pharmacology. His work is very highly cited, with an H-index of 50, more than 20 articles cited >100 times, average citation 32 per paper, and 15 articles being the subject of editorials in major medical journals. He is CIA on an NHMRC Program Grant to study the molecular and cellular basis of liver disease, and has recently held a Centre for Clinical Research Excellence Program grant to improve outcomes for patients with liver disease.

Do you have patients referred to you suffering from NAFLD?
Are you looking for an expert guide to the latest in clinical management?
 
If so, this is the book for you, providing an expert and comprehensive analysis of NAFLD: what it is, why it happens, who is likely to suffer from it, and how to decide on the best management options for your patients.
 
This book focuses clearly on providing first-rate clinical guidance as to the assessment, diagnosis and treatment of patients in the clinical setting, based wherever possible on the latest evidence and scientific understanding of disease mechanisms. With each chapter fully revised and updated with the very latest in AASLD, EASL and Asia-Pacific guidelines, this second edition provides:
* Four brand new chapters, including "NAFLD and cardiovascular risk factors" and "Non-invasive methods to determine severity of NAFLD/ NASH"
* A clear overview on the causative mechanisms of NAFLD
* Self-assessment via key points and multiple-choice questions throughout
* The very latest in clinical drug trials
* Analysis of NAFLD in relation to obesity, diabetes, high cholesterol and liver cancer
* A consideration of NAFLD importance in Asia (particularly including Japan and China) and South America, as well as Europe and North America
NAFLD is a serious condition that is increasing in prevalence globally from year to year. Non-Alcoholic Fatty Liver Disease: A Practical Guide, is essential reading for all hepatologists and health professionals managing patients who have this condition.

List of Contributors, vii
 
1 What is non-alcoholic fatty liver disease (NAFLD), and why is it important? 1
Geoffrey C. Farrell, Arthur J. McCullough, and Christopher P. Day
 
2 NAFLD in the community, 17
Leon A. Adams
 

3 Pathology of NAFLD, 27
Elizabeth M. Brunt and David E. Kleiner
 
4 The natural history of NAFLD, 37
Paul Angulo
 
5 Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH), 46
Isabelle A. Leclercq
 
6 Diabetes and NAFLD: why is the connection important? 62
Elisabetta Bugianesi
 
7 NAFLD and cardiovascular risk factors: implications for vascular disease, 71
Giovanni Targher
 
8 A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer, 84
Shivakumar Chitturi and Geoffrey C. Farrell
 
9 Imaging of NAFLD, 93
Takeshi Yokoo, An Tang, and Claude B. Sirlin
 
10 Non-invasive methods to determine the severity of NAFLD and NASH, 112
Vincent Wai-Sun Wong and Henry Lik-Yuen Chan
 
11 Fatigue, quality of life, and psychosocial issues for people with NAFLD, 122
Julia L. Newton and James Frith
 
12 Physical activity and cardiovascular fi tness in patients with NAFLD: clinical importance and therapeutic implications, 132
Ingrid J. Hickman, Graeme A. Macdonald, and Nuala M. Byrne
 
13 NAFLD, obesity, and bariatric surgery, 149
Philippe Mathurin
 
14 Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management, 157
Quentin M. Anstee, Ann K. Daly, and Christopher P. Day
 
15 NAFLD in children, 171
Ariel E. Feldstein
 
16 The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure, 182
Jonathon W. Schwake, Dawn M. Torres, and Stephen A. Harrison
 
17 Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers, 192
Janine Graham and Helen L. Reeves
 
18 NAFLD in Chinese and South Asian people, 206
Jia-Horng Kao, Deepak Amarapurkar, and Jian-Gao Fan
 
19 Non-alcoholic fatty liver disease in Japan, 217
Takeshi Okanoue, Kohichiroh Yasui, and Yoshito Itoh
 
20 Non-alcoholic fatty liver disease in South America and Hispanic people, 228
Helma Pinchemel Cotrim and Carla Daltro
 
21 Alcohol in non-alcoholic fatty liver disease: an oxymoron or a new standard of care?, 234
Achuthan Sourianarayanane, Srinivasan Dasarathy, and Arthur J. McCullough
 
22 Dietary factors in the pathogenesis and care of patients with fatty liver disease, 248
Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli, and Silvia Di Domizio
 
23 Metabolic factors and steatosis in patients with hepatitis B and C, 260
Francesco Negro
 
24 Drug therapy for NASH: insulin-sensitizing agents (metformin and thiazolidinediones), 271
Mohammad S. Siddiqui and Arun J. Sanyal
 
25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines, 284
Anne Catherine Bürgi and Jean-François Dufour
 
26 Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents, 293
 
Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, and Maurizio Cassader
 
Index, 308
 
Color plate section facing p86